Menu Menu


GSK Financials       Clear


GSK        0001131399    
Filing Date Form Type Description Document
2023-02-23 6-K VIIV HEALTHCARE ANNOUNCES CABENUVA POSITIVE DATA View Document
2023-02-22 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-16 6-K NEJM PUBLISHES GSK RSV OA VACCINE CANDIDATE TRIAL View Document
2023-02-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-14 SC 13G/A SC 13G/A View Document
2023-02-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-10 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-10 6-K JEMPERLI FULL FDA APPROVAL FOLLOWING GARNET TRIAL View Document
2023-02-10 6-K JEMPERLI FDA ODAC POSITIVE OUTCOME View Document
2023-02-06 SC 13G SCHEDULE 13G View Document
2023-02-02 6-K DAPRODUSTAT APPROVED BY US FDA FOR ANAEMIA OF CKD View Document
2023-02-01 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-02-01 6-K TOTAL VOTING RIGHTS View Document
2023-02-01 6-K BENLYSTA GRANTED ORPHAN DRUG DESIGNATION BY US FDA View Document
2023-02-01 6-K FINAL RESULTS View Document
2023-01-30 SC 13G SCHEDULE 13G View Document
2023-01-30 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP View Document
2023-01-20 SC 13D/A AMENDMENT TO FORM SC 13D View Document
2023-01-20 SC 13D/A SCHEDULE 13D/A View Document
2023-01-18 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-01-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-01-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-01-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-01-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2023-01-03 6-K TOTAL VOTING RIGHTS View Document
2022-12-22 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-12-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-12-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-12-15 6-K BOARD AND COMMITTEE CHANGES View Document
2022-12-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-12-07 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION View Document
2022-12-05 6-K TRANSFER OF TREASURY SHARES View Document
2022-12-02 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-12-02 6-K JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCER View Document
2022-12-02 6-K EMA FILE ACCEPTED FOR MOMELOTINIB View Document
2022-12-01 6-K TOTAL VOTING RIGHTS View Document
2022-11-25 6-K GSK PUBLISHES PROVISIONAL 2023 DIVIDEND DATES View Document
2022-11-22 6-K BLENREP US UPDATE View Document
2022-11-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-11-15 6-K BLOCK LISTING INTERIM REVIEW View Document
2022-11-14 3 View Document
2022-11-14 SC 13D/A SCHEDULE 13D/A View Document
2022-11-14 6-K GSK UPDATE: ZEJULA 2L IN US View Document
2022-11-10 6-K SANOFI-GSK COVID BOOSTER VACCINE APPROVED BY EU View Document
2022-11-10 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-11-10 6-K BLOCK LISTING APPLICATION View Document
2022-11-07 6-K DREAMM-3 PHASE III TRIAL FOR BLENREP View Document
2022-11-04 3 ME - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP View Document
2022-11-04 SC 13D ACQUISITION OF BENEFICIAL OWNERSHIP View Document
2022-11-03 6-K IDMC RECOMMENDS GEPOTIDACIN EARLY EFFICACY STOP View Document
2022-11-02 6-K 3RD QUARTER RESULTS View Document
2022-11-02 6-K GSK RSV VACCINE: US FDA PRIORITY REVIEW View Document
2022-11-01 6-K TOTAL VOTING RIGHTS View Document
2022-10-28 6-K EMA ACCEPTS GSK RSV OLDER ADULT VACCINE FOR REVIEW View Document
2022-10-28 6-K EMA VALIDATES MAA FOR CABOTEGRAVIR LA FOR PREP View Document
2022-10-27 6-K GSK ANNOUNCES FDA MEETING OUTCOME ON DAPRODUSTAT View Document
2022-10-27 6-K CONTRAST PHASE III PROGRAMME FOR OTILIMAB UPDATE View Document
2022-10-25 6-K BOARD COMMITTEE CHANGES View Document
2022-10-21 6-K RSV OLDER ADULT VACCINE SUBMISSION IN JAPAN View Document
2022-10-17 6-K MENVEO NEW SINGLE-VIAL APPROVED BY US FDA View Document
2022-10-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-10-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-10-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-10-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-10-13 6-K EFFICACY RESULTS FOR GSK'S OLDER ADULT RSV VACCINE View Document
2022-10-12 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-10-11 6-K US FDA APPROVES BOOSTRIX MATERNAL IMMUNISATION View Document
2022-10-07 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-10-07 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-10-03 6-K TOTAL VOTING RIGHTS View Document
2022-09-30 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-09-26 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-09-26 6-K GSK CHIEF FINANCIAL OFFICER SUCCESSION View Document
2022-09-22 6-K US FDA ODAC REVIEW OF ZEJULA PHASE III NOVA TRIAL View Document
2022-09-22 6-K GSK AND SPERO THERAPEUTICS LICENCE FOR TEBIPENEM View Document
2022-09-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-09-20 4 View Document
2022-09-20 SC 13D/A AMENDMENT TO FORM SC 13D View Document
2022-09-15 25-NSE View Document
2022-09-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-09-08 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-09-06 6-K GSK PROVIDES UPDATE ON FDA REVIEW OF DAPRODUSTAT View Document
2022-09-01 25-NSE View Document
2022-09-01 6-K TOTAL VOTING RIGHTS View Document
2022-08-24 6-K GSK BOARD CHANGES View Document
2022-08-22 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-08-17 6-K FDA NEW DRUG APPLICATION FILE ACCEPTANCE FOR MMB View Document
2022-08-17 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION UPDATE View Document
2022-08-16 6-K GSK COMPLETES ACQUISITION OF AFFINIVAX, INC. View Document
2022-08-12 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION View Document
2022-08-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-08-10 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2022-08-03 6-K CURRENT REPORT OF FOREIGN ISSUER View Document
2022-08-03 SC 13D/A AMENDMENT TO FORM SC 13D View Document
2022-08-01 6-K TOTAL VOTING RIGHTS View Document
2022-08-01 6-K DIRECTOR/PDMR SHAREHOLDING View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299